Insud Pharma is a large, diversified Spanish multinational pharmaceutical group with over 45 years of experience, 10,000 professionals, and 20 industrial plants across more than 50 countries. The company operates API manufacturing, oral solid dose, and injectable manufacturing through its CMO division (Chemo CMO), and biologics/biosimilar manufacturing through its biotech unit mAbxience (majority stake sold to Fresenius Kabi in 2022).
injectable contract manufacturing, oral solid dose, API manufacturing, biosimilar manufacturing (mAbxience), monoclonal antibodies
3 sites worldwide
Involvement in 2 clinical trials
No reviews available yet.
No documents available.